PL2467387T3 - Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu - Google Patents

Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu

Info

Publication number
PL2467387T3
PL2467387T3 PL10747483T PL10747483T PL2467387T3 PL 2467387 T3 PL2467387 T3 PL 2467387T3 PL 10747483 T PL10747483 T PL 10747483T PL 10747483 T PL10747483 T PL 10747483T PL 2467387 T3 PL2467387 T3 PL 2467387T3
Authority
PL
Poland
Prior art keywords
phosphoinositide
kinase inhibitors
heterocyclic compounds
tricyclic heterocyclic
tricyclic
Prior art date
Application number
PL10747483T
Other languages
English (en)
Inventor
Stephen Joseph Shuttleworth
Alexander Richard Liam Cecil
Thomas James Hill
Franck Alexandre Silva
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0914594A external-priority patent/GB0914594D0/en
Priority claimed from GBGB1005584.6A external-priority patent/GB201005584D0/en
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of PL2467387T3 publication Critical patent/PL2467387T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL10747483T 2009-08-20 2010-08-19 Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu PL2467387T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0914594A GB0914594D0 (en) 2009-08-20 2009-08-20 Compounds
GBGB1005584.6A GB201005584D0 (en) 2010-04-01 2010-04-01 Compounds
PCT/GB2010/051370 WO2011021038A1 (en) 2009-08-20 2010-08-19 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
EP10747483.5A EP2467387B1 (en) 2009-08-20 2010-08-19 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.

Publications (1)

Publication Number Publication Date
PL2467387T3 true PL2467387T3 (pl) 2015-08-31

Family

ID=42756474

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10747483T PL2467387T3 (pl) 2009-08-20 2010-08-19 Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu

Country Status (15)

Country Link
US (4) US9200007B2 (pl)
EP (1) EP2467387B1 (pl)
JP (1) JP5746172B2 (pl)
CN (1) CN102498115B (pl)
AU (1) AU2010286168B2 (pl)
BR (1) BR112012003955A2 (pl)
CA (1) CA2771594C (pl)
ES (1) ES2534326T3 (pl)
IL (1) IL217903A (pl)
IN (1) IN2012DN01325A (pl)
MX (1) MX2012002059A (pl)
NZ (1) NZ597983A (pl)
PL (1) PL2467387T3 (pl)
WO (1) WO2011021038A1 (pl)
ZA (1) ZA201200910B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102498115B (zh) 2009-08-20 2016-12-07 卡鲁斯治疗有限公司 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
AU2015268776B2 (en) * 2010-12-16 2017-04-13 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
MX2013006858A (es) 2010-12-16 2013-07-29 Hoffmann La Roche Compuesto triciclicos inhibidores de la pi3k y metodos de uso.
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
EP2897959B1 (en) * 2012-09-20 2017-12-20 UDC Ireland Limited Azadibenzofurans for electronic applications
IN2015DN03235A (pl) 2012-11-07 2015-10-02 Karus Therapeutics Ltd
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
AR095443A1 (es) * 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
US9814037B2 (en) * 2013-06-28 2017-11-07 Intel Corporation Method for efficient channel estimation and beamforming in FDD system by exploiting uplink-downlink correspondence
CN104557955B (zh) * 2013-10-23 2017-05-03 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514760D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
EP3389662B1 (en) 2015-12-16 2021-12-01 Genentech, Inc. Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
GEP20207167B (en) 2016-06-22 2020-10-12 Univ Vanderbilt Positive allosteric modulators of the muscarinic acetylcholine receptor m4
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US11008335B2 (en) 2016-11-07 2021-05-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
CN109863139B (zh) 2016-11-07 2023-02-17 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
CN109862893B (zh) 2016-11-07 2023-02-17 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
GB201702938D0 (en) 2017-02-23 2017-04-12 Univ Southampton Methods of generating and screening compartmentalised peptides libraries
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
MA51036A (fr) 2017-12-05 2021-03-17 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
SG11202005985PA (en) 2018-01-10 2020-07-29 Recurium Ip Holdings Llc Benzamide compounds
WO2022169882A1 (en) 2021-02-03 2022-08-11 Verge Analytics, Inc. Methods and treatment of viral infection caused by sars-cov-2
CN117751127A (zh) * 2021-08-20 2024-03-22 南京大美生物制药有限公司 一种五元含氮杂环并杂芳基类衍生物及其用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP2004502686A (ja) 2000-06-30 2004-01-29 スージェン・インコーポレーテッド ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2004006846A2 (en) 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2005082887A1 (ja) 2004-02-26 2005-09-09 Aska Pharmaceutical Co., Ltd. ピリミジン誘導体
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP1881983B1 (en) 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridines useful as inhibitors of protein kinase
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
MX2008013582A (es) 2006-04-26 2009-01-19 Hoffmann La Roche Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
KR101402474B1 (ko) * 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
WO2008001076A1 (en) 2006-06-26 2008-01-03 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors
CA2669399A1 (en) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
AU2008210455A1 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
US20100063032A1 (en) 2007-03-28 2010-03-11 Debenham John S Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
WO2009094224A1 (en) * 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CA2732087A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as medicaments
AU2009299894A1 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4 -morpholino-pyrido [3, 2 -d] pyrimidines active on Pi3k
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8981087B2 (en) 2009-07-29 2015-03-17 Karus Therapeutics Limited Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
CN102498115B (zh) 2009-08-20 2016-12-07 卡鲁斯治疗有限公司 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
ES2654177T3 (es) 2011-07-27 2018-02-12 Astrazeneca Ab Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
CN104955824B (zh) 2012-11-20 2017-09-22 豪夫迈·罗氏有限公司 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
EP3003309B1 (en) 2013-05-30 2020-09-09 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EP3052494B1 (en) 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazole compounds as inhibitors of t790m containing egfr mutants
EP3054953B1 (en) 2013-10-10 2020-07-01 Acetylon Pharmaceuticals, Inc. Hdac inhibitors in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use

Also Published As

Publication number Publication date
BR112012003955A2 (pt) 2017-09-26
US20190040079A1 (en) 2019-02-07
NZ597983A (en) 2014-05-30
ES2534326T3 (es) 2015-04-21
US20160108057A1 (en) 2016-04-21
CN102498115B (zh) 2016-12-07
US20180009826A1 (en) 2018-01-11
CA2771594C (en) 2018-05-01
IL217903A0 (en) 2012-03-29
JP5746172B2 (ja) 2015-07-08
JP2013502404A (ja) 2013-01-24
EP2467387A1 (en) 2012-06-27
CN102498115A (zh) 2012-06-13
MX2012002059A (es) 2012-04-19
US9580442B2 (en) 2017-02-28
CA2771594A1 (en) 2011-02-24
AU2010286168A1 (en) 2012-03-08
US20120178737A1 (en) 2012-07-12
IL217903A (en) 2017-08-31
AU2010286168B2 (en) 2014-05-15
US10501478B2 (en) 2019-12-10
WO2011021038A1 (en) 2011-02-24
IN2012DN01325A (pl) 2015-06-05
US9938290B2 (en) 2018-04-10
ZA201200910B (en) 2013-05-29
EP2467387B1 (en) 2015-01-07
US9200007B2 (en) 2015-12-01

Similar Documents

Publication Publication Date Title
PL2467387T3 (pl) Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu
IL266563A (en) Heterocyclic compounds used as pdk1 inhibitors
IL261778A (en) New tricyclic compounds
ZA201201124B (en) Heterocyclic compounds as autotaxin inhibitors
IL215258A0 (en) Heterocyclic compounds as autotaxin inhibitors
IL216145A0 (en) Dihydropyrimidinones for use as bace2 inhibitors
IL239081B (en) Benzoxazepine pi3k inhibitor compound
IL218292A0 (en) Heterocyclic compounds for the inhibition of pask
IL220053A0 (en) Novel tricyclic compounds
IL219385A0 (en) N-containing heteroayl derivatives as kaj3 kinase inhibitors
IL200934A0 (en) Spiro substituted compounds as angiogenesis inhibitors
IL200854A0 (en) Spiro substituted compounds as angiogenesis inhibitors
IL218271A0 (en) Heterocyclic compounds as janus kinase inhibitors
IL212142A0 (en) Heterocyclically substituted aryl compounds as hif inhibitors
AP2010005364A0 (en) Novel heterocyclic compounds.
IL220701A0 (en) Tricyclic compounds for use as kinase inhibitors
IL220205A0 (en) Heterocyclic compounds as janus kinase inhibitors
EP2379538A4 (en) HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
IL213935A0 (en) Novel heterocyclic compounds as metap-2 inhibitors
HK1178150A (en) Tricyclic compounds for use as kinase inhibitors
GB0919817D0 (en) Heterocyclic compounds
GB0919816D0 (en) Heterocyclic compounds